XKRX
010600
Market cap663kUSD
Jan 23, Last price
11.00KRW
Name
WellBiotec Co Ltd
Chart & Performance
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.74%
Rev. gr., 5y
-0.12%
Revenues
83.30b
+15.48%
Net income
-21.22b
L-67.31%
CFO
-6.08b
L+45.78%
Dividend
Dec 28, 200514.9931 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Seoul, South Korea, in 1975, Wellbiotec Co., Ltd. operates a multifaceted business both domestically and on the international stage. The company specializes in the manufacturing and distribution of various leather goods, catering to products such as footwear, handbags, automotive interiors, and steering wheel coverings. Beyond its leather operations, Wellbiotec provides extensive logistics solutions, which include consulting, container management, warehousing, customs clearance, and transportation agency services. Furthermore, the company is deeply involved in the healthcare sector, offering product research and development, expert consultation, distribution, and sales for general and specialized medicines, nutritional supplements, diagnostic kits, and cosmeceuticals. Additionally, Wellbiotec extends its reach into the entertainment industry through a casting agency, celebrity nurturing, content creation, and multi-channel network management. Rounding out its diverse activities, the firm also maintains a presence in the food and beverage market.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||